A Systematic Review of NT-proBNP as Prognostic Biomarker for Preeclampsia Complications
DOI:
https://doi.org/10.26911/thejmch.2024.09.02.06Abstract
Background: Preeclampsia can lead to maternal and fetal complications due to its ability to cause multiple organ disorders. Interestingly, N-terminal pro-brain-type natriuretic peptide (NT-proBNP) levels were higher in preeclampsia than in non-preeclampsia, representing cardiovascular mal¬function as the potential cause. Moreover, NT-proBNP also has a potential role in predicting complications that will arise in preeclampsia. This systematic review was performed to determine the role of NT-proBNP plasma levels in predicting maternal and fetal complications in preeclampsia.
Subjects and Method: This systematic review was conducted based on PRISMA-P by previous observational study from scientific databases, namely Hinari, Cochrane Library, ScienceDirect, Scopus, and grey literature in OCLC’s OAISTER between 2006 and 2021. The search keyword used were ((NTproBNP) OR (NT-proBNP) OR (N-terminal pro-BNP) OR (N-terminal pro-Brain Natriuretic Peptide)) AND ((preeclampsia) OR (pre-eclampsia)) AND (pregnancy complications). Newcastle - Ottawa Quality Assessment Scale (NOS) was used to assess quality of included studies.
Results: After study selection, five studies from 156 studies were considered eligible and selected in this systematic review. The results showed that pre-eclampsia complications occurred with NT-proBNP levels above 500 mg/dL, which cardiovascular complications may occurred above 700 mg/dL. NT-proBNP levels were higher in women with maternal complications such as placental abruption, HELLP (Hemolysis, elevated liver enzyme levels, and low platelet levels) syndrome, eclampsia, pulmonary oedema, congestive heart failure, cerebrovascular accident, renal dysfunction, and hypertensive retinopathy. Furthermore, increased NT-proBNP levels were associated with fetal growth restriction, resulting in low birth weight. NT-proBNP was significantly higher in pregnant women due to a combination of pre-existing volume overload and NT-proBNP clearance dysfunction in kidney.
Conclusion: NT-proBNP levels were associated with adverse outcomes in preeclampsia. NT-proBNP serum levels could be used to predict maternal-fetal complications in preeclampsia.
Keywords:
preeclampsia, fetal, maternal, complications, NT-proBNPReferences
Aabidha PM, Cherian AG, Paul E, Helan J. (2015). Maternal and fetal outcome in preeclampsia in a secondary care hospital in South India. J Family Med Prim Care. 4(2): 257–260. https://doi.org/10.4103/22494863.154669.
Adu-Bonsaffoh K, Obed SA, Seffah JD. (2014). Maternal outcomes of hypertensive disorders in pregnancy at Korle Bu Teaching Hospital, Ghana. International Journal of Gynecology and Obstetrics. 127(3): 238–242. https://doi.org/10.1016/j.ijgo.2014.06.010.
Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez F. (2016). N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia. Clin Chim Acta. 463: 150–157. https://doi.org/10.1016/j.cca.-2016.10.033.
Asaduddin AH, Anshari SY, Ali AS, Indarta AF, Bachnas MA, Febrinasari RP, Widyaningsih V (2021). The role of NT-proBNP as prognostic biomarker for preeclampsia complications : a systematic review protocol. Res Sq. https://doi.org/https://doi.org/10.21203/rs.3.rs388263/v1.
Cao, Jia, Zhu. (2019). BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine. Int J Mol Sci. 20(8): 1820. https://doi.org/10.3390/ijms20081820.
Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ (2019). Preeclampsia: risk factors, diagnosis, management, and the cardiovascular impact on the off-spring. J Clin Med. 8(10). https://doi.org/10.3390/jcm8101625.
Fu S, Ping P, Zhu Q, Ye P, Luo L (2018). Brain natriuretic peptide and its biochemical, analytical, and clinical issues in heart failure: a narrative review. Front Physiol. 9. https://doi.org/10.3389/fphys.2018.00692.
Giannubilo SR, Pasculli A, Tidu E, Biagini A, Boscarato V, Ciavattini A (2017). Relationship between maternal hemodynamics and plasma natriuretic peptide concentrations during pregnancy complicated by preeclampsia and fetal growth restriction. Journal of Perinatology. 37(5): 484–487. https://doi.org/10.1038/jp.2016.264.
Gromadziński L, Januszko-Giergielewicz B, Czarnacka K, Pruszczyk P. (2019). NT-proBNP in the prognosis of death or need for renal replacement therapy in patients with stage 3-5 chronic kidney disease. Cardiorenal Med. 9(2): 125–134. https://doi.org/10.1159/000496238.
Hafiz A, Dewantiningrum J, Kristanto H, Pramono MBA. (2021). Serum n-terminal pro b-type natriuretic peptide is associated with maternal complication in pregnancy with severe preeclampsia. Bali Medical Journal. 10(1): 304–308. https://doi.org/10.15562/bmj.v10i1.2162.
Ker JA, Soma-Pillay P. (2018). NT-proBNP: when is it useful in obstetric medicine? Obstet Med. 11(1): 3–5. https://doi.org/10.1177/1753495X17736717.
Kim HM, Choo YS, Seong WJ. (2020). Serum NT-proBNP levels as a marker for cardiopulmonary function in pre-eclampsia. Clin Exp Obstet Gynecol. 47(4): 511–515. https://doi.org/10.31083/J.CEOG.2020.04.5301.
Kumari S, Gupta M, Vardhan H, Saini V, Gupta SK (2017). NT-PROBNP: A biochemical marker of maternal complications in preeclampsia. Journal of Clinical and Diagnostic Research. 11(11): QC12–QC16. https://doi.org/10.7860/JCDR/2017/28713.10855.
Kuwashiro T, Yasaka M, Ito Y, Tokunaga K, Takaguchi G, Nakamura A, Gotoh S, et al. (2016). Significance of BNP for Neurological Severity in Acute Ischemic Stroke. Neurology. 86(16 Supplement): I2.009.
Lafuente-Ganuza P, Carretero F, Lequerica-Fernández P, Fernandez-Bernardo A, Escudero AI, de la Hera-Galarza JM, Garcia-Iglesias D, et al. (2021). NT-proBNP levels in preeclampsia, intrauterine growth restriction as well as in the prediction on an imminent delivery. Clinical Chemistry and Laboratory Medicine (CCLM). 59(6): 1077–1085. https://doi.org/10.1515/cclm20201450
Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, Chappell L. (2019). Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study. Circulation. 140(13): 1050–1060. https://doi.org/10.1161/CIRCULATIONAHA.118.038080.
Mateus J, Newman RB, Zhang C, Pugh SJ, Grewal J, Kim S, Grobman WA, et al. (2019). Fetal growth patterns in pregnancy-associated hypertensive disorders: NICHD fetal growth studies. Am J Obstet Gynecol. 221(6): 635.e1635.e16. https://doi.org/10.1016/j.ajog.2019.06.028.Fetal.
Melchiorre K, Thilaganathan B (2011). Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 23(6): 440–447. https://doi.org/10.1097/GCO.0b013e32834cb7a4.
Nankali A, Malek-Khosravi S, Zangeneh M, Rezaei M, Hemati Z, Kohzadi M. (2013). Maternal complications associated with severe preeclampsia. J Obstet Gynaecol India. 63(2): 112–115. https://doi.org/10.1007/s1322401202830.
Nguyen TX, Nguyen VT, Nguyen-Phan HN, Hoang Bui B. (2022). Serum levels of NT-Pro BNP in patients with preeclampsia. integr blood press control. 15: 43–51. https://doi.org/10.2147/IBPC.S360584.
Ngwenya S (2017). Severe preeclampsia and eclampsia: Incidence, complications, and perinatal outcomes at a low-resource setting, mpilo central hospital, bulawayo, Zimbabwe. Int J Womens Health. 9: 353–357. https://doi.org/10.2147/IJWH.S131934.
Pankiewicz K, Szczerba E, Maciejewski T, Fijałkowska A. (2019). Non-obstetric complications in preeclampsia. Menopause Rev. 18(2): 99–109.
Ramos JGL, Sass N, Costa SHM (2017). Preeclampsia. Rev Bras Ginecol Obstet. 39(9): 496–512. https://doi.org/10.1055/s00371604471.
Rana S, Lemoine E, Granger JP, Karumanchi SA (2019). Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res. 124(7): 1094–1112. https://doi.org/10.1161/CIRCRESAHA.118.313276.
Sadlecki P, Grabiec M, Walentowicz-Sadlecka M (2016). Prenatal clinical assessment of NT-proBNP as a diagnostic tool for preeclampsia, gestational hypertension and gestational diabetes mellitus. PLoS One. 11(9): e0162957–e0162957. https://doi.org/10.1371/journal.pone.0162957.
Seong WJ, Kim SC, Hong DG, Koo TB, Park IS. (2011). Aminoterminal probrain natriuretic peptide levels in hyperten-sive disorders complicating pregnancy. Hypertens Pregnancy. 30(3): 287–294. https://doi.org/10.3109/10641950903115046.
Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA (1993). Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 169(4): 1000–1006. https://doi.org/10.1016/00029378(93)90043i.
Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH (2010). The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 133(1): 14–23. https://doi.org/10.1309/AJCP60HTPGIGFCNK.
Thilaganathan B (2017). Cardiovascular origins of Preeclampsia. Pregnancy Hypertension: An International J Womens Cardiovasc Health. 7: 62–63. https://doi.org/10.1016/j.preghy.2016.10.022.
Thilaganathan B. (2018). Preeclampsia and the cardiovascular-placental axis. Ultrasound Obstet Gynecol. 51(6): 714–717. https://doi.org/10.1002/uog.19081.
Tolcher MC, Mendez-Figueroa H, Aagaard KM (2018). Complications of preeclampsia. in critical care obstetrics (eds J.P. Phelan, L.D. Pacheco, M.R. Foley, G.R. Saade, G.A. Dildy and M.A. Belfort). 837–872. https://doi.org/10.1002/9781119129400.ch50.
Yücesoy G, Ozkan S, Bodur H, Tan T, Calişkan E, Vural B, Corakçi A. (2005). Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Arch Gynecol Obstet. 273(1): 43–49. https://doi.org/10.1007/s0040400507413.
